EHA 2024 | Reducing chemotherapy-induced adverse events in patients with AML
Fabio Guolo
• 16 Jun 2024
Fabio Guolo, MD, University of Genoa, Genoa, Italy, discusses ways to reduce the adverse events related to intensive chemotherapy in the treatment of patients with acute myeloid leukemia (AML). First, using liposomal formulations, such as that used by CPX-351, can help target the chemotherapy to areas where it is most needed and reduce systemic effects. Second, introducing more targeted agents in AML treatment could reduce the need for chemotherapy drugs. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
